Morphotek

Exton, PA, United States

Morphotek

Exton, PA, United States
SEARCH FILTERS
Time filter
Source Type

Browse tables and figures, 05 company profiles spread across 102 pages at http://www.reportsnreports.com/reports/998417-global-botulinum-market-research-report-2017.html . Global Botulinum Market Report 2017 is a professional and in-depth survey on the current state of the Botulinum industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Botulinum market analysis is provided for the international market including development history, competitive landscape analysis, and major regions' development status. Market Segment by Regions, this report splits Global into several key Region, with production, consumption, revenue, market share and growth rate of Botulinum in these regions, from 2012 to 2022 (forecast), like North America, China, Europe, Japan, India, Southeast Asia split by product type, with production, revenue, price, market share and growth rate of each type Split by application, this report focuses on consumption, market share and growth rate of Botulinum in each application. This report studies Botulinum in global market, focuses on top manufacturers in global market, with sales, price, revenue and market share for each manufacturer, covering XOMA Corporation, AlphaVax Microbiotix, Molecular Targeting Technologies and Morphotek. Order a copy at http://www.reportsnreports.com/purchase.aspx?name=998417 . The 'Global and Chinese Botulinum Toxins Industry, 2012-2022 Market Research Report' is a professional and in-depth study on the current state of the global Botulinum Toxins industry with a focus on the Chinese market. The report provides key statistics on the market status of the Botulinum Toxins manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Firstly, the report provides a basic overview of the industry including its definition, applications and manufacturing technology. Then, the report explores the international and Chinese major industry players in detail. In this part, the report presents the company profile, product specifications, capacity, production value, and 2012-2017 market shares for each company. Through the statistical analysis, the report depicts the global and Chinese total market of Botulinum Toxins industry including capacity, production, production value, cost/profit, supply/demand and Chinese import/export. The total market is further divided by company, by country, and by application/type for the competitive landscape analysis The Global Botulinum Toxins Industry 2017 Market Research Report is a professional and in-depth study on the current state of the Botulinum Toxins industry. Firstly, the report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Botulinum Toxins market analysis is provided for the Global market including development history, competitive landscape analysis, and major regions' development status. Secondly, development policies and plans are discussed as well as manufacturing processes and cost structures. This report also states import/export, supply and consumption figures as well as cost, price, revenue and gross margin. This report studies Botulinum Neurotoxins in Global market, focuses on price, sales, revenue of each type in Global. This report also focuses on the sales (consumption), production, import and export of Botulinum Neurotoxins in global market, forecast to 2021, from 2016. Firstly, this report focuses on price, sales, revenue and growth rate of each type, as well as the types and each type price of key manufacturers, through interviewing key manufacturers. Second on basis of segments by manufacturers, this report focuses on the sales, price of each type, average price of Botulinum Neurotoxins, revenue and market share, for key manufacturers. The Botulinum Neurotoxins industry development trends and marketing channels are also analyzed and the feasibility of new investment projects are assessed and overall research conclusions offered. With the tables and figures the report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals. ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. We provide 24/7 online and offline support to our customers.


Browse tables and figures, 05 company profiles spread across 102 pages at http://www.reportsnreports.com/reports/998417-global-botulinum-market-research-report-2017.html . Global Botulinum Market Report 2017 is a professional and in-depth survey on the current state of the Botulinum industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Botulinum market analysis is provided for the international market including development history, competitive landscape analysis, and major regions' development status. Market Segment by Regions, this report splits Global into several key Region, with production, consumption, revenue, market share and growth rate of Botulinum in these regions, from 2012 to 2022 (forecast), like North America, China, Europe, Japan, India, Southeast Asia split by product type, with production, revenue, price, market share and growth rate of each type Split by application, this report focuses on consumption, market share and growth rate of Botulinum in each application. This report studies Botulinum in global market, focuses on top manufacturers in global market, with sales, price, revenue and market share for each manufacturer, covering XOMA Corporation, AlphaVax Microbiotix, Molecular Targeting Technologies and Morphotek. Order a copy at http://www.reportsnreports.com/purchase.aspx?name=998417 . The 'Global and Chinese Botulinum Toxins Industry, 2012-2022 Market Research Report' is a professional and in-depth study on the current state of the global Botulinum Toxins industry with a focus on the Chinese market. The report provides key statistics on the market status of the Botulinum Toxins manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Firstly, the report provides a basic overview of the industry including its definition, applications and manufacturing technology. Then, the report explores the international and Chinese major industry players in detail. In this part, the report presents the company profile, product specifications, capacity, production value, and 2012-2017 market shares for each company. Through the statistical analysis, the report depicts the global and Chinese total market of Botulinum Toxins industry including capacity, production, production value, cost/profit, supply/demand and Chinese import/export. The total market is further divided by company, by country, and by application/type for the competitive landscape analysis The Global Botulinum Toxins Industry 2017 Market Research Report is a professional and in-depth study on the current state of the Botulinum Toxins industry. Firstly, the report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Botulinum Toxins market analysis is provided for the Global market including development history, competitive landscape analysis, and major regions' development status. Secondly, development policies and plans are discussed as well as manufacturing processes and cost structures. This report also states import/export, supply and consumption figures as well as cost, price, revenue and gross margin. This report studies Botulinum Neurotoxins in Global market, focuses on price, sales, revenue of each type in Global. This report also focuses on the sales (consumption), production, import and export of Botulinum Neurotoxins in global market, forecast to 2021, from 2016. Firstly, this report focuses on price, sales, revenue and growth rate of each type, as well as the types and each type price of key manufacturers, through interviewing key manufacturers. Second on basis of segments by manufacturers, this report focuses on the sales, price of each type, average price of Botulinum Neurotoxins, revenue and market share, for key manufacturers. The Botulinum Neurotoxins industry development trends and marketing channels are also analyzed and the feasibility of new investment projects are assessed and overall research conclusions offered. With the tables and figures the report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals. ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. We provide 24/7 online and offline support to our customers.


ADCC is a function used by several commercial and experimental-stage therapeutic antibodies to target the host's immune system to destroy tumor cells that are bound by the antibody2. Farletuzumab has been shown in previous in vivo preclinical studies to utilize immune-effector activities including ADCC and complement mediated cytotoxicity (CDC) to kill target cells, as well as induce an intracellular death program called autophagy3-5.  While the relationship of these pathways on optimal tumor cell killing is still being studied, evidence has shown that removal of at least one of these components results in significantly diminished farletuzumab anti-tumor activity3,4.  These data now support the scientific relationship between CA125 levels and potential clinical outcomes of patients when treated with farletuzumab. To address this hypothesis, the effects of CA125 on farletuzumab pharmacologic activity when combined with standard of care chemotherapy are being further investigated in a clinical trial currently recruiting patients with low serum CA125 (NCT02289950). About Morphotek Morphotek®, Inc., a subsidiary of Eisai Inc., is a clinical-stage biotechnology company focused on developing novel classes of biological-based products to treat cancer, inflammatory and infectious diseases.  Our mission is to develop novel, targeted therapies that attack underlying disease pathways and overcome the immunosuppressive effects by tumors on immune-mediated experimental therapies.  Our diverse pipeline includes clinical-stage monoclonal antibodies to lead targets folate receptor alpha, mesothelin and endosialin, as well as antibody drug conjugates and bispecific antibodies to undisclosed targets in preclinical development.  Our mission is supported by the proprietary cutting-edge technologies in antibody engineering, manufacturing and screening optimization platforms, along with our expertise in developing diagnostics to support patient selection and therapeutic strategy.  For more information, please visit www.morphotek.com. About Eisai Inc. At Eisai Inc., human health care (hhc) is our goal. We give our first thought to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs. Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Each group functions as an end-to-end global business with discovery, development, and marketing capabilities. Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania; and our global demand chain organization resides in Maryland and North Carolina. To learn more about Eisai Inc., please visit us at www.eisai.com/US and follow us on Twitter and LinkedIn.


MORAb-202 is a novel ADC that uses a cathepsin-cleavable linker to combine investigational farletuzumab with a microtubule inhibitor payload, eribulin*.  Farletuzumab is a humanized antibody targeting human folate receptor alpha (FRA) and has been studied in clinical trials for FRA-expressing tumors.  FRA expression is observed in a large number of cancers, including endometrial, gastric, non-small cell lung, ovarian and triple-negative breast, but is largely absent from normal tissue.  Eribulin mesylate (Halaven®) is approved in the U.S. for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for metastatic disease, including an anthracycline and a taxane in either the adjuvant or metastatic setting. *Any ADC employing eribulin as a payload is investigational and has not been approved by regulatory authorities.  For more information on Halaven® (eribulin mesylate), please see www.halaven.com or contact Eisai's Medical Information toll-free number 1.888.274.2378. "We are pleased to have this opportunity to present MORAb-202 at the upcoming 8th Annual World ADC," said Nicholas Nicolaides, President and CEO of Morphotek. "Based on the preclinical data to be presented, we are excited to begin transitioning MORAb-202 into the clinical development stage later this year." Morphotek will also present three posters on Wednesday, September 20: In April 2017, Morphotek launched an ADC Services business that leverages its proprietary REsidue-SPEcific Conjugation Technology (RESPECT™) and eribulin-linker platform to assist clients with development of a site-specific bioconjugate-ready monoclonal antibody and ADC through in vivo safety and efficacy validation.  Additional services include manufacture of GMP clinical trial material, conducting GLP toxicology studies and development of IHC companion diagnostics for patient screening.  For more information on Morphotek's ADC Services business and RESPECT platform, please visit us at Booth #2 at the 8th Annual World ADC or contact adcservices@morphotek.com. About Morphotek Morphotek®, Inc., a subsidiary of Eisai Inc., is a clinical-stage biotechnology company focused on developing novel classes of biological-based products to treat cancer, inflammatory and infectious diseases.  Our mission is to develop novel targeted therapies that attack underlying disease pathways, and in oncology indications, that can overcome the immunosuppressive effects by tumors on immune-mediated experimental therapies.  Our diverse pipeline includes clinical-stage monoclonal antibodies to lead targets folate receptor alpha, mesothelin and endosialin, as well as antibody-drug conjugates and bispecific antibodies to undisclosed targets in preclinical development.  Our mission is supported by proprietary cutting-edge technologies in antibody engineering, manufacturing and screening optimization platforms, along with our expertise in developing diagnostics to support patient selection and therapeutic strategy.  For more information, please visit www.morphotek.com. At Eisai Inc., human health care (hhc) is our goal. We give our first thought to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs. Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Each group functions as an end-to-end global business with discovery, development, and marketing capabilities. Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania; and our global demand chain organization resides in Maryland and North Carolina. To learn more about Eisai Inc., please visit us at www.eisai.com/US and follow us on Twitter and LinkedIn. About Halaven® (eribulin mesylate) Injection Halaven® (eribulin mesylate) is a microtubule dynamics inhibitor indicated for the treatment of patients with: The antibody drug conjugate (ADC) employing eribulin as a payload is investigational and has not been approved by regulatory authorities. Discovered and developed by Eisai, eribulin is a synthetic analog of halichondrin B, a natural product that was isolated from the marine sponge Halichondria okadai.  First in the halichondrin class, Halaven is a microtubule dynamics inhibitor.  Eribulin is believed to work primarily via a tubulin-based mechanism that causes prolonged and irreversible mitotic blockage, ultimately leading to apoptotic cell death.  Additionally, in preclinical studies of human breast cancer, eribulin demonstrated complex effects on the tumor biology of surviving cancer cells, including increases in vascular perfusion resulting in reduced tumor hypoxia, and changes in the expression of genes in tumor specimens associated with a change in phenotype, promoting the epithelial phenotype, opposing the mesenchymal phenotype.  Eribulin has also been shown to decrease the migration and invasiveness of human breast cancer cells. Neutropenia: Severe neutropenia (ANC <500/mm3) lasting >1 week occurred in 12% of patients with mBC and liposarcoma or leiomyosarcoma.  Febrile neutropenia occurred in 5% of patients with mBC and 2 patients (0.4%) died from complications.  Febrile neutropenia occurred in 0.9% of patients with liposarcoma or leiomyosarcoma, and fatal neutropenic sepsis occurred in 0.9% of patients.  Patients with mBC with elevated liver enzymes >3 × ULN and bilirubin >1.5 × ULN experienced a higher incidence of Grade 4 neutropenia and febrile neutropenia than patients with normal levels.  Monitor complete blood cell counts prior to each dose, and increase the frequency of monitoring in patients who develop Grade 3 or 4 cytopenias.  Delay administration and reduce subsequent doses in patients who experience febrile neutropenia or Grade 4 neutropenia lasting >7 days. Peripheral Neuropathy: Grade 3 peripheral neuropathy occurred in 8% of patients with mBC (Grade 4=0.4%) and 22% developed a new or worsening neuropathy that had not recovered within a median follow-up duration of 269 days (range 25-662 days).  Neuropathy lasting >1 year occurred in 5% of patients with mBC.  Grade 3 peripheral neuropathy occurred in 3.1% of patients with liposarcoma and leiomyosarcoma receiving HALAVEN and neuropathy lasting more than 60 days occurred in 58% (38/65) of patients who had neuropathy at the last treatment visit.  Patients should be monitored for signs of peripheral motor and sensory neuropathy.  Withhold HALAVEN in patients who experience Grade 3 or 4 peripheral neuropathy until resolution to Grade 2 or less. Embryo-Fetal Toxicity: HALAVEN can cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential to use effective contraception during treatment with HALAVEN and for at least 2 weeks following the final dose.  Advise males with female partners of reproductive potential to use effective contraception during treatment with HALAVEN and for 3.5 months following the final dose. QT Prolongation: Monitor for prolonged QT intervals in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, and electrolyte abnormalities.  Correct hypokalemia or hypomagnesemia prior to initiating HALAVEN and monitor these electrolytes periodically during therapy.  Avoid in patients with congenital long QT syndrome. Adverse Reactions In patients with mBC receiving HALAVEN (eribulin mesylate) Injection, the most common adverse reactions (≥25%) were neutropenia (82%), anemia (58%), asthenia/fatigue (54%), alopecia (45%), peripheral neuropathy (35%), nausea (35%), and constipation (25%).  Febrile neutropenia (4%) and neutropenia (2%) were the most common serious adverse reactions.  The most common adverse reaction resulting in discontinuation was peripheral neuropathy (5%). In patients with liposarcoma and leiomyosarcoma receiving HALAVEN, the most common adverse reactions (≥25%) reported in patients receiving HALAVEN were fatigue (62%), nausea (41%), alopecia (35%), constipation (32%), peripheral neuropathy (29%), abdominal pain (29%), and pyrexia (28%).  The most common (≥5%) Grade 3-4 laboratory abnormalities reported in patients receiving HALAVEN were neutropenia (32%), hypokalemia (5.4%), and hypocalcemia (5%).  Neutropenia (4.9%) and pyrexia (4.5%) were the most common serious adverse reactions.  The most common adverse reactions resulting in discontinuation were fatigue and thrombocytopenia (0.9% each). Lactation: Because of the potential for serious adverse reactions in breastfed infants from eribulin mesylate, advise women not to breastfeed during treatment with HALAVEN and for 2 weeks after the final dose. Hepatic and Renal Impairment: A reduction in starting dose is recommended for patients with mild or moderate hepatic impairment and/or moderate or severe renal impairment. For more information about HALAVEN, click here for the full Prescribing Information.


Takeda Pharmaceutical Company Limited (TOKYO : 4502) et Lightstone Ventures ont annoncé aujourd'hui le lancement de Cerevance, une société de neuroscience spécialisée dans la découverte et le développement de nouvelles thérapies contre les troubles neurologiques et psychiatriques. La société utilisera une nouvelle technologie créée au laboratoire du Howard Hughes Medical Institute du Dr. Nathaniel Heintz, Ph.D. à l'Université Rockefeller. Takeda donnera le coup d'envoi à la nouvelle société en déployant une équipe de recherche en neuroscience composée de 25 personnes de son site de Cambridge, au Royaume-Uni, y compris le vétéran du secteur Mark Carlton, Ph.D., un espace de laboratoire entièrement équipé et des licences à un portefeuille de programmes de médicaments au stade préclinique et clinique. Cerevance bénéficie d'un financement de 36 millions USD, ce qui inclut un financement de Série A de 21,5 millions USD des sociétés Takeda et Lightstone Ventures, qui rejoindront chacune le conseil d'administration de Cerevance. « Sept des dix causes principales d'invalidité au monde sont des troubles du système nerveux central », a déclaré Brad Margus, président-directeur général de Cerevance. « Avec une équipe bien capitalisée et confirmée et des programmes de médicaments prometteurs déjà en place, nous espérons développer rapidement un pipeline de thérapies dans la clinique, de pair avec l'accélération d'une approche réellement novatrice envers les maladies cérébrales basée sur notre nouvelle technologie. » « Nous sommes ravis de rassembler certains de nos meilleurs scientifiques, programmes et ressources de découverte dans un projet hautement ciblé misant de plus en plus l'innovation externe », a confié pour sa part le Dr. Andrew Plump, M.D., Ph.D., directeur médical et scientifique chez Takeda. « Quand nous avons annoncé la fermeture de notre site de recherche à Cambridge, au Royaume-Uni, notre objectif était de trouver un site d'externalisation innovant pour nos programmes et nos scientifiques SNC les plus prometteurs dans un cadre entrepreneurial. Cerevance est un excellent exemple de notre nouvelle stratégie R&D. » « Lightstone se réjouit de diriger le financement de Série A de Cerevance et estime que la combinaison de l'expertise et de la technologie à plate-forme de Nat Heintz, de l'équipe de gestion confirmée et passionnée, et du solide soutien de Takeda constitue une opportunité d'investissement de départ incontournable », ajoute Jason Lettmann, associé chez Lightstone Ventures. « La société Cerevance jouit d’une position unique pour offrir une technologie de pointe en vue du développement de traitements contre des maladies du système nerveux central qui touchent des millions de personnes dans le monde. » Ce n'est pas la première fois que Takeda, Heintz et Margus joignent leurs efforts. En 2009, Takeda a investi dans, et collaboré par la suite avec la start-up de découverte de médicaments SNC Envoy Therapeutics, dont Heintz et Margus sont les fondateurs, et qui a également obtenu une technologie sous licence de Rockefeller University. Takeda a fini par acquérir Envoy en 2012. À propos de Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited (TOKYO : 4502) est une société pharmaceutique mondiale axée sur la R&D dont la mission est d'améliorer la santé et l'avenir des patients en traduisant la science en médicaments susceptibles de changer la vie. Takeda concentre ses efforts de recherche sur l’oncologie, la gastroentérologie et les domaines thérapeutiques du système nerveux central. La société gère également des programmes de développement spécifiques dans des maladies cardiovasculaires spécialisées et dans des candidats de stade avancé pour les vaccins. Les activités de R&D de Takeda ont lieu à la fois en interne et avec des partenaires, l'objectif de la société étant de se maintenir à l’avant-garde de l’innovation. Ses nouveaux produits innovants, notamment dans les domaines de l'oncologie, du système nerveux central et de la gastroentérologie, ainsi que sa présence sur des marchés émergents, stimulent la croissance de Takeda. Les plus de 30 000 employés de Takeda s'engagent à améliorer la qualité de vie des patients en collaborant avec des partenaires de soins de santé de la société basés dans plus de 70 pays. Pour plus d'information, visiter http://www.takeda.com/news/ À propos de Lightstone Ventures La société Lightstone Ventures a été fondée en 2012 par Life Science Partners of Advanced Technology Ventures (ATV) et Morgenthaler Ventures pour se spécialiser dans les dispositifs médicaux et les produits biopharmaceutiques de pointe. L'équipe Lightstone gère activement les portefeuilles de science de la vie Morgenthaler et ATV de plus de 30 sociétés de science de la vie et a participé à plusieurs des plus importantes débouchées financées par capital-risque dans le domaine des soins de santé au cours des dix dernières années y compris : Acceleron, Ardian, FivePrime, FoldRx, Hypnion, MicroVention, Morphotek, Plexxikon, Portola, Proteolix, Scioderm, Transcend, Threshold, Twelve et Zeltiq. Lightstone est une firme internationale dont les bureaux sont situés à Menlo Park, en Californie ; Boulder, dans le Colorado ; Boston, dans le Massachusetts ; Dublin, en Irlande ; et Singapour. Pour de plus amples informations, visiter http://www.lightstonevc.com/. Déclarations prévisionnelles de Takeda Ce communiqué de presse contient « des déclarations prévisionnelles ». Les déclarations prévisionnelles comprennent toutes les déclarations autres que des énoncés de faits historiques, y compris des plans, des stratégies et attentes pour l’avenir, des déclarations concernant l’échéancier prévu des dépôts de demandes et des approbations relatifs à la transaction, la date prévue de l’achèvement de la transaction, la capacité à exécuter la transaction ou à satisfaire aux diverses conditions de clôture, de revenus et de rentabilité à venir en termes de croissance ou d’hypothèses sous-jacentes à ce qui précède. Les déclarations faites au futur et au conditionnel et l'emploi de mots tels que « anticiper », « s’attendre à », « projeter », « continuer », « croire », « planifier », « estimer », « pro forma », « avoir l’intention », « potentiel », « cibler », « prévisions », « orientation », « perspectives », « chercher », « supposer », « peut » et autres expressions similaires sont destinés à être interprétés dans le cadre de ces déclarations prévisionnelles. Les déclarations prévisionnelles reposent sur des estimations et des hypothèses établies par la direction qui sont jugées raisonnables, même si elles sont par nature incertaines et difficiles à prévoir. Les investisseurs et les détenteurs de valeurs sont priés de ne pas se fier indûment à ces déclarations prévisionnelles. Les déclarations prévisionnelles impliquent des risques et des incertitudes susceptibles d’entraîner un écart sensible entre les résultats réels ou l’expérience et ceux ou celles mentionnés ou sous-entendus dans les déclarations prévisionnelles. Certains de ces risques et incertitudes comprennent, mais ne sont pas limités aux faits suivants : les approbations réglementaires requises pour la transaction pourraient ne pas être obtenues en temps opportun, voire pas du tout ; les conditions de clôture de la transaction pourraient ne pas être satisfaites ; les pressions et les évolutions de la concurrence ; les lois et règlements applicables ; le succès ou l’échec des programmes de mise au point de produits ; les actions des autorités réglementaires et le calendrier de celles-ci ; les variations des taux de change ; et les revendications ou les préoccupations concernant l’innocuité ou l’efficacité des produits commercialisés ou des produits candidats en cours de développement.


News Article | November 7, 2016
Site: www.newsmaker.com.au

MarketStudyReport.com adds “Global Gout Therapeutics Market 2016-2020” new report to its research database. The report spread across 59 pages with table and figures in it. The research analysts forecast the global gout therapeutics market to grow at a CAGR of 17.16% during the period 2016-2020. About Gout Therapeutics Gout is one type of arthritis, which is caused by the high levels of uric acid in the blood. The main symptoms of gout are sudden attack of burning pain, swelling in a joint, and stiffness, usually in toe. If it is not treated, over time, it can harm tendons, joints, and other tissues. NSAIDs and urate-lowering agents are preferred treatment options for gout. Browse full table of contents and data tables at https://www.marketstudyreport.com/reports/global-gout-therapeutics-market-2016-2020/ Covered in this report The report covers the present scenario and the growth prospects of the global gout therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-label drugs used for the treatment of gout and the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs. The market is divided into the following segments based on geography: Americas APAC EMEA Research report, Global Gout Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Key vendors AstraZeneca Horizon Pharma Takeda Pharmaceuticals Other prominent vendors Ablynx Alder Biopharmaceuticals Antares Pharma Astellas Pharma Boehringer Ingelheim Can-Fite BioPharma Celgene Celltrion ChemoCentryx CymaBay Therapeutics Eisai Eli Lilly Gilead Sciences GlaxoSmithKline Incyte Ironwood Pharmaceuticals JW Pharmaceutical KaloBios Pharmaceuticals Lexicon Pharmaceuticals LG Life Sciences Merck Morphotek Novartis Novo Nordisk Regeneron Pharmaceuticals Sandoz Sanofi Santarus Selecta Biosciences Teijin Pharma UCB Vertex Pharmaceuticals. Market driver Introduction of novel urate-lowering agents For a full, detailed list, view our report Market challenge Low physician and patient awareness For a full, detailed list, view our report Market trend Focus on regenerative medicines For a full, detailed list, view our report Key questions answered in this report What will the market size be in 2020 and what will the growth rate be? What are the key market trends? What is driving this market? What are the challenges to market growth? Who are the key vendors in this market space? What are the market opportunities and threats faced by the key vendors? What are the strengths and weaknesses of the key vendors? To receive personalized assistance, write to us @ [email protected] with the report title in the subject line along with your questions or call us at +1 866-764-2150


WiseGuyReports.Com Publish a New Market Research Report On – “Immunotherapy Drugs Market Global Potential Growth,Share,Demand and Analysis Of Key Players Research Report Forecasts to 2020”. This market research report presents a comprehensive segmentation of the global immunotherapy drugs market by type of immunotherapy (mAbs, vaccines, immune checkpoint inhibitors, non-specific immunotherapies, and others), by therapy area (oncology, infectious disease, autoimmune and inflammatory disorders, respiratory diseases, and others), and by geography (the Americas, APAC, and EMEA). Key vendors are AbbVie, Amgen, Bristol-Myers Squibb, F.Hoffmann-La Roche, Johnson & Johnson, and Merck. Overview of the global immunotherapy drugs market  The market research analyst predicts that the global immunotherapy drugs market will grow at a steady CAGR of close to 12% by 2020. During a rise in cancer and a number of autoimmune diseases, the need for immunotherapy drugs is on the rise. Furthermore, with the increasing demand for mAbs, the market for immunotherapy drugs will have a positive outlook until the end of the forecast period. mAbs have a high affinity for specific disease cells and areas that need treatment. Consequently, they can be used for therapies like radioimmunotherapy and antibody-directed enzyme prodrug therapy. The augmented usage of these antibodies in drug development will help to bolster the market’s revenue generating capacity over the course of the next four years. For more information or any query mail at [email protected] An important factor impelling the prospects for growth in this market is the emergence of biosimilars. Unlike generic drugs, which have active pharmaceutical ingredients similar to original drugs, biosimilars are almost identical to their originator biologic compounds. Since biosimilars help to make treatments more accessible to patients and are less expensive than biologics, their sale among the end users is anticipated to increase significantly over the next few years. Segmentation by type of immunotherapy and analysis of the immunotherapy drugs market  - mAbs  - Vaccines  - Immune checkpoint inhibitors  - Non-specific immunotherapies During 2015, the mAbs segment dominated this market and accounted for an impressive market share of nearly 61%. The development of new drugs and the entry of new molecules like zanolimumab, elotuzumab, obinutuzumab, and onartuzumab into the market will aid in the growth of this market segment during the forecast period. Geographical segmentation and analysis of the immunotherapy drugs market  - Americas  - APAC  - EMEA The Americas dominated the global market with over 50% market share in 2015. The market is flourishing in this region due to the higher incidences of cancer, infectious diseases, and autoimmune diseases in the US. Additionally, factors such as the high affordability of therapies due to the presence of well-structured reimbursement plans will also spur the prospects for market growth until 2020. Competitive landscape and key vendors  The global market for immunotherapy drugs is highly competitive due to the presence of a number of large and small vendors. Many of these vendors have a huge global presence and enter into strategic alliances to aid in the manufacture and marketing of essential drugs. Safety and effectiveness of drugs are key factors, which will give vendors an edge in the marketplace. Key vendors in this market are - AbbVie  Amgen  Bristol-Myers Squibb  F.Hoffmann-La Roche  Johnson & Johnson  Merck  Other prominent vendors are AB Science. Ablynx, Acorda Therapeutics, ADC Therapeutics, Aduro Biotech, Advantagene, Advaxis, Agensys, Agenus, Alder Biopharmaceuticals, AlphaVax, Altor BioScience, Antares Pharma, Antigen Express, Argos Therapeutics, Astellas Pharma, AstraZeneca, AVAX Technologies, Bavarian Nordic, Baxter, Bayer, Biogen, Biotech Pharmaceutical, Biothera, Boehringer Ingelheim, Can-Fite BioPharma, Celgene, Celldex Therapeutics, Celltrion, Cel-Sci, ChemoCentryx, Chugai Pharmaceutical, Coherus BioSciences, CTI BioPharma, CureVac, Daiichi Sankyo, Eisai, Eli Lilly, Fortress Biotech, Galena Biopharma, Genexine, Genmab, Gilead Sciences, GSK, GlobeImmune, Gradalis, Heat Biologics, Hospira, Idera, Inmatics, ImmunoCellular Therapeutics, Immunomedics, ImmuPharma, Immutep, Incyte, Inovio Pharmaceuticals, Intas Pharmaceuticals, Invion, ISA Pharmaceuticals, Janssen Biotech, Juvaris Biotherapeutics, KaloBios Pharmaceuticals, Kyowa Hakko Kirin, Lexicon Pharmaceuticals, MedImmune, Morphotek, Neovii Biotech, Northwest Biotherapeutics, Novartis, NovaRx, Novo Nordisk, OncoMed Pharmaceuticals, Oncothyreon, Oncovir, Opexa Therapeutics, Oxford BioMedica, Pfizer, Prima BioMed, Principia, Progenics, Provectus Biopharmaceuticals, Regeneron, Sandoz, Sanofi, Santarus, Seattle Genetics, Sotio, Spectrum Pharmaceuticals, Takeda, TG Therapeutics, Transgene, UbiVac, UCB, Vaccinex, Vaccinogen, Vaxon Biotech, Vertex Pharmaceuticals, Vical, Vitae Pharmaceuticals, and XBiotech. Key questions answered in the report include  - What will the market size and the growth rate be in 2020?  - What are the key factors driving the global immunotherapy drugs market?  - What are the key market trends impacting the growth of the global immunotherapy drugs market?  - What are the challenges to market growth for immunotherapy drugs?  - Who are the key vendors in the global immunotherapy drugs market?  - What are the market opportunities and threats faced by the vendors in the immunotherapy drugs market?  - Trending factors influencing the market shares of the Americas, APAC, and EMEA.  - What are the key outcomes of the five forces analysis of the global immunotherapy drugs market? For more information or any query mail at [email protected] Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories.


— The report provides comprehensive information on the therapeutics under development for Psoriatic Arthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Psoriatic Arthritis and features dormant and discontinued projects. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Complete report on Psoriatic Arthritis - Pipeline Review, H2 2016 addition with 53 market data tables and 15 figures, spread across 231 pages is available at http://www.reportsnreports.com/reports/755895-psoriatic-arthritis-pipeline-review-h2-2016.html This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries,conferences,SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis 3SBio,AbbVie, AbGenomics International,Alteogen ,Amgen,Biocon ,Bionovis, Bristol-Myers Squibb Company, Celgene Corporation, Coherus BioSciences, Eli Lilly and Company, Forward Pharma A/S, Genor BioPharma Co Ltd, Innovent Biologics, Johnson & Johnson, Kadmon Corporation, KPI Therapeutics,Momenta Pharmaceuticals, Morphotek Mycenax Biotech, NeuClone Pty Ltd, Novo Nordisk A/S Oncobiologics, Pfizer Sandoz International Inquire before buying http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=755895(This is a premium report price at US$2000 for a single user PDF license). • The report provides a snapshot of the global therapeutic landscape of Psoriatic Arthritis • The report reviews pipeline therapeutics for Psoriatic Arthritis by companies and universities/research institutes based on information derived from company and industry-specific sources • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities • The report reviews key players involved Psoriatic Arthritis therapeutics and enlists all their major and minor projects • The report assesses Psoriatic Arthritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type • The report summarizes all the dormant and discontinued pipeline projects • The report reviews latest news related to pipeline therapeutics for Psoriatic Arthritis • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage • Identify and understand important and diverse types of therapeutics under development for Psoriatic Arthritis • Identify potential new clients or partners in the target demographic • Develop strategic initiatives by understanding the focus areas of leading companies • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics • Devise corrective measures for pipeline projects by understanding Psoriatic Arthritis pipeline depth and focus of Indication therapeutics • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline For more information, please visit http://www.reportsnreports.com


News Article | November 16, 2016
Site: www.newsmaker.com.au

DelveInsight’s, “Peripheral Lung Cancer -Pipeline Insights, 2016”, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the 12 pipeline drugs that fall under the category of Peripheral Lung Cancer. Peripheral lung cancer usually begins in tissues that lie near the outer parts of the lungs, and may be diagnosed later in due course of time. The report also provides the recent trends as these days’ companies are focusing on the Targeted Therapy for cancer majorly on the inner working of the lung cancer cells and process, which will control their growth and spread. Morphotek’s Farletuzumab is the only monoclonal antibody in Phase II competing against the other small molecules in development along with Solitomab of Amgen in Phase I.  Recent report of Delveinsight covers drugs that are being developed with novel approach to target or intervene along the pathways of tumorigenesis. Currently in pipeline, we can observe close competition between the Phase II drugs of Big Pharma such as Pfizer and Eisai along with mid tier companies such as Hanmi, Axelar and Morphotek. Boehringer is leading both in market as well as in pipeline with Afatinib in Phase III stage of development. Scope:  • The new report, provides a Peripheral Lung Cancer Landscape across the globe  • The report provides drug profiles which includes product description, MOA, licensors & collaborators, development partner and chemical information  • Comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, Preclinical and Discovery stages  • Coverage of the Peripheral Lung Cancer pipeline on the basis of target, MOA, route of administration, technology involved and molecule type  • The report reviews key players involved in the therapeutics development for Peripheral Lung Cancer and also provide company profiling  • Pipeline products coverage based on various stages of development from NDA filings to discovery.  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type. Reasons to Buy:  • Complete Pipeline intelligence and complete understanding over therapeutics development for Peripheral Lung Cancer  • Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.  • Devise corrective measures for pipeline projects by understanding Peripheral Lung Cancer pipeline depth and focus of Indication therapeutics  • Developing strategic initiatives to support your drug development activities.  • Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.  • Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline  • Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions For more information or any query mail at [email protected]


Thomas A.,U.S. National Institutes of Health | Maltzman J.,Morphotek | Hassan R.,U.S. National Institutes of Health
Lung Cancer | Year: 2013

Folate is essential for proliferating cells and folate transport pathways and folate-dependent metabolic processes show promise as targets for anti-neoplastic therapy. Folate receptor α (FOLR1), a folate transporter, is an attractive target for anti-neoplastic therapy due to its high affinity for folate, restricted range of expression in normal tissue and differential over-expression in malignant tissue. FOLR1 is expressed in non-small cell lung cancer, with a higher expression in adenocarcinoma compared with squamous cell carcinoma. Farletuzumab is a monoclonal antibody targeting FOLR1 which in pre-clinical studies led to cytotoxicity of FOLR1-expressing cells, inhibited tumor growth in animal models and showed limited reactivity with normal tissue. In phase I/II trials, farletuzumab was well tolerated as a single-agent and in combination, without additive toxicity with chemotherapy. An ongoing phase II, double blind, placebo-controlled study is evaluating farletuzumab in patients with FOLR1 expressing metastatic adenocarcinoma of lung. © 2013.

Loading Morphotek collaborators
Loading Morphotek collaborators